LIFT BioSciences is pioneering a new class of immunotherapy for hard-to-treat cancers based on allogeneic Immuno-Modulatory Alpha Neutrophils (IMANs)®. Our proprietary, platform harnesses neutrophils’ innate tumour-homing and infiltrating attributes, combined with their ability to directly kill cancer cells and safely orchestrate broader immune responses, offering a powerful and antigen-independent treatment option to overcome cancer resistance mechanisms, like suppressive tumour environment and immune evasion.
Backed by deep neutrophil biology expertise and a scalable manufacturing platform, LIFT is advancing a differentiated pipeline with application across multiple solid cancers.
London BioScience Innovation Centre
2 Royal College Street
London
NW1 0NH
United Kingdom
Tel: +44 (0) 20 7691 1122